Molecular Pharmacology (USA), Ltd. Stock Price

Molecular Pharmacology (USA), Ltd., a development stage company, develops and commercializes pain and inflammation management products primarily in Australia, Europe, and the United States. The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops Tripeptofen, an analgesic and anti-inflammatory molecule for the treatment of every-day pain. Its products are available in various dosage forms, formulations, line extensions, and package configurations. The company focuses on marketing its products through pharmaceutical distributors, and through collaborative dealings with companies. It also has an agreement with Dermatology Development Corporation to develop and market a range of therapeutic, cosmetic, and cosmeceutical products based on the ThermaLIFE product range and its active ingredients. The company is based in Perth, Australia. Molecular Pharmacology (USA), Ltd. is a subsidiary of PharmaNet Group Limited.